Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) from a sell rating to a hold rating in a research note published on Saturday.

Several other equities research analysts have also commented on ALLO. Oppenheimer reduced their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, May 14th. Citigroup reduced their price target on shares of Allogene Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, May 15th. Royal Bank Of Canada restated an “outperform” rating and issued a $10.00 price target on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Piper Sandler reduced their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Citizens Jmp lowered shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 14th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.44.

Get Our Latest Stock Analysis on Allogene Therapeutics

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $1.13 on Friday. The stock has a market cap of $250.72 million, a price-to-earnings ratio of -1.02 and a beta of 0.36. Allogene Therapeutics has a 1 year low of $0.86 and a 1 year high of $3.78. The firm has a 50-day moving average of $1.20 and a two-hundred day moving average of $1.42.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. Research analysts expect that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Institutional Trading of Allogene Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Caption Management LLC purchased a new stake in Allogene Therapeutics during the fourth quarter worth $32,000. Wealth Enhancement Advisory Services LLC purchased a new stake in Allogene Therapeutics during the first quarter worth $28,000. Brooklyn Investment Group purchased a new stake in Allogene Therapeutics during the first quarter worth $45,000. CANADA LIFE ASSURANCE Co boosted its holdings in Allogene Therapeutics by 142.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock worth $35,000 after buying an additional 18,314 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Allogene Therapeutics during the second quarter worth $37,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

See Also